🧵 Top 10 ASCO 2025 Myeloma Abstracts – A Thread Here’s what stands out from this year’s abstracts - more to come after presentations! Updates in bispecifics, MRD-guided therapy, CAR-T, and trispecifics. 👇

#ASCO25 And another one! Journal of Clinical Oncology: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated 2018-2019. All likely would have died; instead, 1/3 alive & well 5 yrs out with no maintenance! 👏 Beginning of the end for #plateauenvy? (cc Nina Shah)

#Myeloma Paper of the Day: Review of monoclonal gammopathy of cutaneous significance (MGCS), a paraproteinemia w/ serious cutaneous sequelae which warrants co-management w/ hematology & treatment to address underlying Ig- or plasma cell disorder: pubmed.ncbi.nlm.nih.gov/40466947/. #mmsm

Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

Update on CAR T-cells in CLL with VuMedi Perlmutter Cancer Center at NYU Langone Health #CLL vumedi.com/video/overview…

Always a pleasure to speak with Dr. John Sweetenham and the #ASCODailyNews Podcast about updates in hematologic malignancies from #ASCO25 #mmsm Perlmutter Cancer Center at NYU Langone Health Link: dailynews.ascopubs.org/do/podcast-pre…

Join me and my colleague Dr. Marta Wronska this Tuesday at 12pm ET a #ASCOMedEdCoP grand rounds on use of simulation for educating fellows. Registration link below. #MedEd NYU Grossman Long Island School of Medicine ASCO OncMedEdCoP docs.google.com/forms/d/e/1FAI…

Preparing for Oncology Board Certification, Career Transitions, and Combating Burnout cancernetwork.com/view/preparing… via CancerNetwork®

Had a chance to speak with CancerNetwork alongside Eric K. Singhi, MD, MinhTri Nguyen, MD (he/him), Nerea Lopetegui-Lia, MD and Marc Braunstein, MD, PhD, FACP about one of the most underdiscussed—and overwhelming—periods in our careers: preparing for the boards while transitioning from fellowship to faculty. The facts: 📚

Nice #MMsm work by Josh Gustine Andrew Yee, MD Noopur Raje et al. CHIP with BCMA CAR-T doesn’t affect PFS or SPM (n=104), but risk on ICAHT needing support: # mut matters. Q is of course if SC boost can help here - probably depends on when in tx journey cells were collected!

To new residents/fellows starting this week, a bit of advice: after 15 years of training following undergrad, what is still most important to my patients is being attentive to their concerns, sometimes at odd hours. Patients value how much you care, not just how much you know.

Why do many regulatory oncology phase III trials not accrue sufficient US patients? This issue came up repeatedly at today’s ODAC for belantamab for myeloma. And I can address it at least for myeloma. 1) In our healthcare system, opening a trial in a timely manner is a

Given the more recent results of the MIDAS study (Perrot NEJM 2025) and others such as STaMINA (Hari JCO 2020), is there still a role for tandem autologous transplants in #myeloma? #mmsm

While I think the alterantive anti-BCMA agents such as bispecifics and CART are highly effective, the FDA voted against the approval of #blenrep due to ocular toxicity despite positive efficacy data in the randomized DREAMM-7 and -8 studies. #mmsm

It’s thrilling to work at an NCI Comprehensive Cancer Center like Perlmutter Cancer Center at NYU Langone Health which is ranked highly by USNWR. Of course it’s not just about ranking, but about how much we all care for our patients and communities.

Science matters and is the underpinning of what we do in medicine. It’s not perfect, easy, or inexpensive, but well worth the investment.

Join me and my colleagues from Perlmutter Cancer Center at NYU Langone Health on September 30 for a virtual discussion for the patient and caregiver community on novel therapies for #leukemia, #lymphoma, and multiple #myeloma. Registration link below: tinyurl.com/54cybx88

Excited to serve as a coach for the ASH 2026-2027 Quality Improvement Training Institute (QITI), helping to enhance quality initiatives across the landscape of interdisciplinary care. Perlmutter Cancer Center at NYU Langone Health NYU Grossman Long Island School of Medicine hematology.org/education/clin…

Registration is open for the ASCO 2025 Oncology Training Program Leadership Retreat on Nov 6-7. Heme/onc fellowship leaders/coordinators will share tips and updates on improving fellowship training. I will be speaking about integrating AI. To register: tinyurl.com/2v985a4a